-transparent.png){kind=logo}
In the focal infarction model of the rat middle cerebral artery (MCA), the thalamus of the occluded side becomes gradually atrophic, mainly because of retrograde degeneration. We determined whether basic fibroblast growth factor (bFGF) administered intracisternally could prevent this thalamic atrophy. We occluded the left MCA through a small cranial opening, and animals were then divided into two groups. One group received intracisternal injections of recombinant bFGF (1 microgram dissolved in 0.1 ml of saline with 2% rat serum) starting 1 day after occlusion and repeated once a week to a total dose of 4 micrograms by four injections. The other group received vehicle solution by the same schedule. The animals were perfused and fixed at 28 days after occlusion, and histological examination was made at the level of the caudoputamen and thalamus. In the bFGF-treated rats, the area of the posterior ventral thalamus of the occluded side was 93% of that of the contralateral side, i.e., significantly larger than in the normal saline-treated rats (75%, p less than 0.01). The infarction size was not statistically different in the two groups. Microscopic observation indicated that normal-saline-treated animals showed shrinkage and disappearance of thalamic neurons, whereas bFGF-treated groups showed preservation of thalamic neurons. Computerized analysis of the cell size substantiated this observation. To assess the effect of bFGF on astrocytes, bFGF or vehicle solution was injected into normal rats, and their histology was evaluated at 1, 2, and 4 weeks after injection. The bFGF-injected group showed a significant increase in glial fibrillary acidic protein-positive astrocytes in the brain tissue facing the ventriculocisternal system.(ABSTRACT TRUNCATED AT 250 WORDS)
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
January 1994,
Restorative neurology and neuroscience,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
April 1999,
Neuroreport,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
April 1989,
Neuroscience letters,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
August 2009,
Tissue engineering. Part A,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
November 1994,
Brain research,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
November 1999,
Nihon rinsho. Japanese journal of clinical medicine,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
August 2005,
Nihon rinsho. Japanese journal of clinical medicine,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
August 1994,
Brain research. Molecular brain research,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
April 1995,
Neurological research,
K Yamada, and
A Kinoshita, and
E Kohmura, and
T Sakaguchi, and
J Taguchi, and
K Kataoka, and
T Hayakawa
March 1988,
Nature,
